Melanoma patients harboring FGFR4 Mut showed a similar tendency, whose survival was longer than those with FGFR4 Wt, though the difference was not statistically significant (mOS: 49.27 months vs. 31.30 months; HR 0.66, 95%CI 0.40-1.09; P = 0.17) (Figure 4D). Here, FGFR4 is linked to melanoma.